Report #2832648

Overview

Sex

Male

Age

Age unknown

State

CA

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

Incorrect Route of Administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a male patient who received MMR (Priorix) (batch number KH2BD, expiry date 01-JAN-2026) for prophylaxis. On an unknown date, the patient received Priorix (intramuscular). On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Incorrect Route of Administration). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-MAR-2025 The pharmacist had a question regarding one of GlaxoSmithKline vaccines the Mmr vaccine, the Priorix. So, it was this only subcutaneously only. The pharmacist asked but what happens if it actually had been given intramuscularly which led to subcutaneous injection formulation administered by other route. The pharmacist reported, like was there any side effects for that.